Foundation fighting blindness fund sells $2.75m in Opus Genetics stock

On September 30, 2026, the Foundation Fighting Blindness Retinal Degeneration Fund, a director and 10% owner of Opus Genetics, Inc., sold 556,000 shares of the company's common stock. The transaction amounted to $2,755,980, with shares traded between $4.95 and $5.29 each. The fund's weighted average price for these sales was $4.9568 per share.

Following the sale, the fund owned 3,236,171 shares of Opus Genetics common stock. Opus Genetics' stock was trading at $4.58 at the time of the sale, slightly below the fund's sale prices. The stock has shown significant gains year-to-date, surging 128% and over the past year, 144%. Although InvestingPro analysis suggests the stock is modestly overvalued at current levels, with two additional insights available to subscribers, it has delivered high returns over the last year.

The Foundation Fighting Blindness Retinal Degeneration Fund is considered a director by deputization due to the board appointments of Adrienne Graves, PhD, and Jean Bennett, MD, PhD, both of whom are members of the board of directors of Foundation Fighting Blindness, Inc. The fund's board of directors makes investment decisions on behalf of its sole member, Foundation Fighting Blindness, Inc. Recently, Opus Genetics has garnered attention from various analysts, with Wedbush raising its price target to $13 and maintaining an Outperform rating, H.C.

Wainwright reaffirming a Buy rating with an $8 price target, and Citizens maintaining a Market Outperform rating with an $12 price target. TD Cowen also kept a Buy rating, noting upcoming clinical trial results expected to show significant efficacy data.